Bright Minds Biosciences (DRUG) Free Cash Flow (2020 - 2026)

Bright Minds Biosciences has reported Free Cash Flow for 7 years, with the latest figure at -$6.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 498.9% year-over-year to -$6.7 million; the trailing twelve-month figure through Mar 2026 stood at -$20.0 million (down 9572.95% YoY), and the FY2025 full-year result was -$6.3 million, down 365.66% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$6.7 million, down from -$4.2 million in the prior quarter.
• The five-year high for Free Cash Flow was $2.9 million in Q1 2022, with the low at -$19.2 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$2.2 million across 5 years, with a median of $597467.2 in 2024.
• The largest YoY upside for Free Cash Flow was 182.9% in 2025 against a maximum downside of 4562.31% in 2025.
• Bright Minds Biosciences' Free Cash Flow stood at $2.0 million in 2022, then sank by 69.23% to $603852.1 in 2023, then surged by 77.16% to $1.1 million in 2024, then sank by 489.85% to -$4.2 million in 2025, then slumped by 61.67% to -$6.7 million in 2026.
• The last three Free Cash Flow figures came in at -$6.7 million (Q1 2026), -$4.2 million (Q4 2025), and -$921379.0 (Q3 2025), per Business Quant data.